Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Biopharma partnership intensifying purification
Sponsored PublicationsDSP?Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides selected insights on Catalent’s findings from the collaboration.
Biopharma partnership – intensifying purification
Sponsored PublicationsDSP Tosoh Bioscience recently launched Octave© BIO, the first in a series of MCC instruments
targeting all stages of biomolecule manufacturing. Here, Tosoh discusses the potential of MCC to help alleviate downstream bottlenecks and a process intensification collaboration they recently performed with Catalent Biologics. Emily Schirmer, Interim General Manager at Catalent Biologics, provides selected insights on Catalent’s findings from the collaboration.
Biontech leaves; what does Germany do?
BackgroundIn soccer, such a transfer would raise tempers: A superstar leaves his team because he no longer trusts it to succeed. A warning sign, a headline event, fodder for weeks of debate in the media. Something similar has just happened to the biotech industry, but things remain strangely quiet in the fan block of Germany’s top research – whispers at best, just whispers, but no outcry anywhere.
Biomanufacturing: Step up and speak up
OpinionIn a world where biotechnology has been enabling products and processes for decades, it’s time to step out from behind the technology and claim the resulting products and their value in our everyday life. It needs higher visibility and recognition of impact, moving beyond its ‘enabling’ brand which forever makes it sound like the benefits are just around the corner, rather than the existing significant economic and industrial impact.
European VCs join US$105m financing of US Mediar Thx
Latest NewsMediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Neurodegenerative disorders are being fought with €28m
Latest NewsDanish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.
Pfizer-Seagen: Acquisition in the works
Latest NewsPfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology.
Iktos SA raises €15.5m in Series A financing
Latest NewsParis-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
Collaboration to fight cancer
Latest NewsThe charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.
Noema Pharma AG closes Series B financing
Latest NewsNoema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline.